Clinical Trials Logo

Clinical Trial Summary

In myotonia congenita (MC), mutations in the CLCN1 gene coding a key chloride channel expressed in muscle cells cause myotonia. On examination, the myotonia can be demonstrated as delayed muscle relaxation of muscle contractions after mechanical stimulations. Existing literature describe no muscle weakness in MC patients, however a recent muscle MRI study in non-dystrophic myotonia patients found structural abnormalities in affected muscles when examined using T1 and STIR imaging. The question remains whether the signs of structural changes in the muscle are merely due to the myotonia, or long-term effects of elevated stress of the tissue, and if so, whether those changes lead to clinically significant loss of contractile properties of the muscle. This study examines if the contractile properties of myotonic muscles are impaired in MC patients. 40 patients with Thomsens disease (n=20) and Beckers disease (n=20), respectively, will be included along with 20 healthy controls. Peak muscle torque is measured in the hand by hand dynamometer and in the thigh and calf muscles with a Biodex System 4 Pro Dynamometer and the cross-sectional area of the muscles are examined on T1-weighed and Dixon-MRI-scan. With the obtained data peak torque in strength tests, muscle hypertrophy, fat fraction in muscle tissue and contractility of the muscles, compared with healthy controls, will be assessed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04799366
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase
Start date February 1, 2021
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06136416 - Pilot Study for the Development of an Activity and Quality of Life Questionnaire for the Follow-up of Patients With Non-dystrophic Myotonia N/A
Recruiting NCT05639257 - Treatment of Myotonia - Lamotrigine Versus Namuscla N/A
Completed NCT00832000 - Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia Phase 2
Recruiting NCT05017155 - MExiletine Versus Lamotrigine in Non-Dystrophic Myotonias Phase 3